No black box warning on record for Tibsovo

As of the latest FDA labeling reviewed, Tibsovo (IVOSIDENIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Tibsovo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS QTc Interval Prolongation : Monitor electrocardiograms and electrolytes. If QTc interval prolongation occurs, dose reduce or withhold, then resume dose or permanently discontinue TIBSOVO ( 2.3 , 5.2 ). Guillain-Barré Syndrome : Monitor patients for signs and symptoms of new motor and/or sensory findings. Permanently discontinue TIBSOVO in patients who are diagnosed with

No black box warning on record for Tibsovo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS QTc Interval Prolongation : Monitor electrocardiograms and electrolytes. If QTc interval prolongation occurs, dose reduce or withhold, then resume dose or permanently discontinue TIBSOVO ( 2.3 , 5.2 ). Guillain-Barré Syndrome : Monitor patients for signs and symptoms of new motor and/or sensory findings. Permanently discontinue TIBSOVO in patients who are diagnosed with

Tibsovo Black Box Warning

No black box warning on record for Tibsovo

Other warnings & precautions

Tibsovo Black Box Warning

No black box warning on record for Tibsovo

Other warnings & precautions